BlinkLab (ASX:BB1) completed testing of the first patient in its digital diagnostic trial for autism at PriMED Clinical Research in Ohio, according to a Wednesday filing with the Australian bourse.
The study aims to validate the BlinkLab Dx1 neurological test as a diagnostic aid for clinicians in early assessment of developmental disorders, the filing said.
PriMED, along with North Shore Pediatric Therapy in Chicago, will participate in the initial study with 100 participants, with data set to be released in the third quarter of the year, per the filing.
Shares rose 7% in afternoon trade Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.